[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE041797T2 - Lipoprotein-komplexek és elõállításuk és alkalmazásuk - Google Patents

Lipoprotein-komplexek és elõállításuk és alkalmazásuk

Info

Publication number
HUE041797T2
HUE041797T2 HUE14150349A HUE14150349A HUE041797T2 HU E041797 T2 HUE041797 T2 HU E041797T2 HU E14150349 A HUE14150349 A HU E14150349A HU E14150349 A HUE14150349 A HU E14150349A HU E041797 T2 HUE041797 T2 HU E041797T2
Authority
HU
Hungary
Prior art keywords
manufacturing
lipoprotein complexes
uses therof
therof
lipoprotein
Prior art date
Application number
HUE14150349A
Other languages
English (en)
Inventor
Jean-Louis Dasseux
Daniela Carmen Oniciu
Rose Ackermann
Original Assignee
Cerenis Therapeutics Holding Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerenis Therapeutics Holding Sa filed Critical Cerenis Therapeutics Holding Sa
Publication of HUE041797T2 publication Critical patent/HUE041797T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE14150349A 2011-02-07 2012-02-06 Lipoprotein-komplexek és elõállításuk és alkalmazásuk HUE041797T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161440371P 2011-02-07 2011-02-07
US201161452630P 2011-03-14 2011-03-14
US201161487263P 2011-05-17 2011-05-17

Publications (1)

Publication Number Publication Date
HUE041797T2 true HUE041797T2 (hu) 2019-05-28

Family

ID=45592833

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE12703947A HUE042314T2 (hu) 2011-02-07 2012-02-06 Lipoprotein komplexek és azok gyártása és alkalmazásai
HUE14150349A HUE041797T2 (hu) 2011-02-07 2012-02-06 Lipoprotein-komplexek és elõállításuk és alkalmazásuk

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE12703947A HUE042314T2 (hu) 2011-02-07 2012-02-06 Lipoprotein komplexek és azok gyártása és alkalmazásai

Country Status (27)

Country Link
US (8) US20120232005A1 (hu)
EP (4) EP2767546B1 (hu)
JP (4) JP6219170B2 (hu)
KR (1) KR20140053848A (hu)
CN (4) CN105294859A (hu)
AU (1) AU2012214672B2 (hu)
CA (1) CA2826158A1 (hu)
CY (2) CY1121317T1 (hu)
DK (3) DK2673296T3 (hu)
ES (2) ES2716349T3 (hu)
HK (1) HK1198834A1 (hu)
HR (2) HRP20190072T1 (hu)
HU (2) HUE042314T2 (hu)
IL (1) IL227634B (hu)
IN (1) IN2013DN07828A (hu)
LT (2) LT2673296T (hu)
MX (2) MX343907B (hu)
PH (1) PH12016500191A1 (hu)
PL (2) PL2767546T3 (hu)
PT (2) PT2673296T (hu)
RS (2) RS58275B1 (hu)
RU (2) RU2017126088A (hu)
SG (2) SG192693A1 (hu)
SI (2) SI2767546T1 (hu)
TW (2) TW201240671A (hu)
WO (1) WO2012109162A1 (hu)
ZA (1) ZA201305628B (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2012000048A1 (en) 2010-06-30 2012-01-05 Csl Limited A reconstituted high density lipoprotein formulation and production method thereof
DK2673296T3 (en) 2011-02-07 2019-02-18 Cerenis Therapeutics Holding Sa LIPOPROTEIN COMPLEXES AND PREPARATION AND APPLICATIONS THEREOF
US9125943B2 (en) * 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
KR20150123796A (ko) * 2013-02-28 2015-11-04 에이전시 포 사이언스, 테크놀로지 앤드 리서치 크로마틴 결핍 세포 배양 수확물로부터의 항체들의 크로마토그래프 정제
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
BR112015023558A2 (pt) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa métodos para a síntese de esfingomielinas e dihidroesfingomielinas
JP6530394B2 (ja) * 2013-08-08 2019-06-12 シーエスエル、リミテッド 混入物除去方法
EP2853259A1 (en) * 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
US20150316566A1 (en) * 2014-05-02 2015-11-05 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
KR101671580B1 (ko) * 2014-08-26 2016-11-02 영남대학교 산학협력단 미녹시딜 수용액 제조방법
US10307491B2 (en) 2015-01-30 2019-06-04 The Regents Of The University Of Michigan Liposomal particles comprising biological molecules and uses thereof
JP2018516847A (ja) 2015-03-25 2018-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 生体高分子薬を送達するための組成物及び方法
WO2016154542A2 (en) * 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for treating cardiovascular related disorders
CN109661238B (zh) 2016-07-27 2023-07-25 哈里斯制药公司 治疗红细胞疾病的治疗组合
WO2018029505A1 (en) 2016-08-11 2018-02-15 Cerenis Therapeutics Holding Sa Cer-001 therapy for treating familial primary hypoalphalipoproteinemia
JP2020505456A (ja) * 2017-01-23 2020-02-20 エイチディーエル セラピューティクス インコーポレイテッドＨｄｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． コレステロール関連疾患の治療方法
ES2681124B1 (es) 2017-03-08 2019-06-19 Fund Imdea Alimentacion Usos medicos de la apolipoproteina a y de activadores de la misma
ES2984286T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
ES2984285T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Cargómeros
KR20210027427A (ko) * 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 재조합 단백질 생산 방법
JP2020138941A (ja) * 2019-02-28 2020-09-03 国立研究開発法人理化学研究所 バイセル及びその利用
CA3156906A1 (en) 2019-11-20 2021-05-27 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
AU2021254856A1 (en) 2020-04-16 2022-11-10 Abionyx Pharma Sa CER-001 therapy for treating kidney disease
WO2021209808A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Cer-001 therapy for treating kidney disease
JP2023522889A (ja) 2020-04-16 2023-06-01 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法
MX2023003877A (es) 2020-10-01 2023-04-18 Abionyx Pharma Sa Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
WO2022125878A1 (en) * 2020-12-11 2022-06-16 The Regents Of The University Of Michigan Compositions and methods for preventing, attenuating, and treating medical conditions with shdl nanoparticles
WO2022150631A1 (en) * 2021-01-08 2022-07-14 Hdl Therapeutics, Inc Systems and methods for reducing low attenuation plaque and/or plaque burden in patients
JP2024514154A (ja) 2021-04-15 2024-03-28 アビオニクス ファーマ エスエー 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用
CA3218096A1 (en) * 2021-05-19 2022-11-24 Viktoria Kheifets Blood plasma fractions for use in liver regeneration
US20230289963A1 (en) * 2022-03-10 2023-09-14 Cleerly, Inc. Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2024003612A2 (en) 2022-06-28 2024-01-04 Abionyx Pharma Sa Compounds and processes for the synthesis of sphingomyelins
KR20240009061A (ko) * 2022-07-13 2024-01-22 (재)씨젠의료재단 혈청 내 다중 아포지단백질의 직접정량 방법
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
AU587989B2 (en) 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
WO1986004144A1 (en) 1984-12-31 1986-07-17 International Genetic Engineering, Inc. Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
GB8625435D0 (en) 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
IT1229996B (it) 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
WO1993000443A1 (en) 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification of recombinant apolipoprotein e from bacteria
US5408038A (en) * 1991-10-09 1995-04-18 The Scripps Research Institute Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
AU5457294A (en) 1992-10-29 1994-05-24 Board Of Regents, The University Of Texas System Adenovirus-mediated ldl receptor gene transfer and targeting
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US5643757A (en) 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
EP0751961A1 (en) 1994-03-22 1997-01-08 Research Corporation Technologies, Inc. Eating suppressant peptides
IL109558A (en) 1994-05-04 2004-08-31 Yissum Res Dev Co DNA structures Derived from the SV40 virus that include DNA sequences External
US5932536A (en) 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
SE9603068D0 (sv) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
GB9919713D0 (en) 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
DE60031419T2 (de) 1999-08-25 2007-09-27 Immunex Corp., Thousand Oaks Zusammensetzungen und verfahren für verbesserte zellkultur
AU7025201A (en) 2000-07-03 2002-01-14 Gala Design Inc Expression vectors
US20030224415A1 (en) 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
JP2004524805A (ja) 2000-07-03 2004-08-19 ギャラ デザイン インコーポレイテッド 複数の組み込みベクターを含む宿主細胞
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP1335938B1 (en) * 2000-11-10 2010-09-22 F. Hoffmann-La Roche Ltd. Apolipoprotein construct
ATE510847T1 (de) 2000-11-20 2011-06-15 Univ Illinois Membrangerüstproteine
WO2002068455A2 (en) 2001-02-23 2002-09-06 Immunex Corporation Efficient recovery of correctly refolded proteins
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
AU2002340825B2 (en) 2001-08-20 2007-07-05 Csl Behring Ag HDL for the treatment of stroke and other ischemic conditions
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
CA2486127C (en) 2002-05-17 2014-03-11 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
EP1545576A2 (en) 2002-07-30 2005-06-29 Esperion Therapeutics Inc. Methods of using non-human animal apoliprotein a-i protein
WO2004043363A2 (en) * 2002-11-06 2004-05-27 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
WO2005011620A2 (en) * 2003-07-03 2005-02-10 Lipid Sciences Inc. Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
AU2005275009B2 (en) * 2004-07-16 2011-12-08 Trustees Of Tufts College Apolipoprotein A1 mimetics and uses thereof
WO2006012632A2 (en) 2004-07-23 2006-02-02 Xencor, Inc. Apolipoprotein a-1 derivatives with altered immunogenicity
US8206750B2 (en) * 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
CN101253195A (zh) * 2005-08-26 2008-08-27 科莱尼斯医疗控股公司 用于在乳酸菌中制备载脂蛋白基因产物的组合物和方法
US8541236B2 (en) * 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
US20080293102A1 (en) * 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
WO2008141230A1 (en) * 2007-05-09 2008-11-20 Lawrence Livermore National Security, Llc Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
CN103408658A (zh) 2007-08-17 2013-11-27 Csl百灵有限公司 α-1-抗胰蛋白酶和载脂蛋白A-I的纯化方法
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
EP2212351B1 (en) * 2007-10-23 2017-09-13 The Cleveland Clinic Foundation Oxidant resistant apolipoprotein a-1 and mimetic peptides
CA2727811A1 (en) * 2008-06-13 2009-12-17 Proyecto De Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
PL2939683T3 (pl) 2009-02-16 2017-07-31 Cerenis Therapeutics Holding Sa Mimetyki apolipoproteiny A-I
US10525152B2 (en) * 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
DK2673296T3 (en) 2011-02-07 2019-02-18 Cerenis Therapeutics Holding Sa LIPOPROTEIN COMPLEXES AND PREPARATION AND APPLICATIONS THEREOF
JP2014509646A (ja) * 2011-03-25 2014-04-21 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク ペグ化ヒトｈｄｌ粒子およびその製造方法

Also Published As

Publication number Publication date
US20160095901A1 (en) 2016-04-07
EP2767546B1 (en) 2018-10-17
DK2673296T3 (en) 2019-02-18
US20140213501A1 (en) 2014-07-31
RU2627173C2 (ru) 2017-08-03
CN105294859A (zh) 2016-02-03
JP2022050603A (ja) 2022-03-30
EP3466969A1 (en) 2019-04-10
SG10201801372YA (en) 2018-04-27
CY1121318T1 (el) 2020-05-29
US10328119B2 (en) 2019-06-25
JP2020176122A (ja) 2020-10-29
US20240000887A1 (en) 2024-01-04
LT2673296T (lt) 2019-02-25
AU2012214672B2 (en) 2015-10-01
JP2018076286A (ja) 2018-05-17
US11376309B2 (en) 2022-07-05
JP2014506884A (ja) 2014-03-20
SI2767546T1 (sl) 2019-03-29
MX343907B (es) 2016-11-28
MX2013009083A (es) 2014-02-03
EP2673296A1 (en) 2013-12-18
HRP20190072T1 (hr) 2019-03-08
CA2826158A1 (en) 2012-08-16
EP2673296B1 (en) 2018-10-24
EP4400511A2 (en) 2024-07-17
TW201737935A (zh) 2017-11-01
DK3466969T3 (da) 2024-07-22
CN107337728B (zh) 2023-05-23
US20120232005A1 (en) 2012-09-13
SI2673296T1 (sl) 2019-03-29
HRP20190138T1 (hr) 2019-03-22
US11998587B2 (en) 2024-06-04
ES2716349T3 (es) 2019-06-12
MX355159B (es) 2018-04-06
EP4400511A3 (en) 2024-09-04
HK1198834A1 (en) 2015-06-12
US10322163B2 (en) 2019-06-18
IN2013DN07828A (hu) 2015-07-03
PT2767546T (pt) 2019-01-28
CN107337728A (zh) 2017-11-10
CN105288589A (zh) 2016-02-03
RU2017126088A (ru) 2019-01-31
RS58275B1 (sr) 2019-03-29
IL227634A0 (en) 2013-09-30
IL227634B (en) 2020-05-31
KR20140053848A (ko) 2014-05-08
PH12016500191A1 (en) 2017-10-18
PL2767546T3 (pl) 2019-04-30
TW201240671A (en) 2012-10-16
PL2673296T3 (pl) 2019-03-29
WO2012109162A1 (en) 2012-08-16
JP6219170B2 (ja) 2017-10-25
US9187551B2 (en) 2015-11-17
NZ613524A (en) 2015-10-30
JP7009559B2 (ja) 2022-01-25
ES2717455T3 (es) 2019-06-21
PT2673296T (pt) 2019-01-31
US20150152164A1 (en) 2015-06-04
DK2767546T3 (en) 2019-02-04
RU2013139066A (ru) 2015-03-20
ZA201305628B (en) 2014-04-30
LT2767546T (lt) 2019-02-25
HUE042314T2 (hu) 2019-06-28
EP2767546A1 (en) 2014-08-20
US20230372441A1 (en) 2023-11-23
CY1121317T1 (el) 2020-05-29
SG192693A1 (en) 2013-09-30
CN103443123B (zh) 2020-05-29
AU2012214672A1 (en) 2013-05-02
US20190298800A1 (en) 2019-10-03
US11969456B2 (en) 2024-04-30
JP6720126B2 (ja) 2020-07-08
EP3466969B1 (en) 2024-05-08
US20220362336A1 (en) 2022-11-17
RS58243B1 (sr) 2019-03-29
CN103443123A (zh) 2013-12-11

Similar Documents

Publication Publication Date Title
HRP20190072T1 (hr) Lipoproteinski kompleksi i njihova proizvodnja i uporaba
HUS2100012I1 (hu) 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-gátlók
EP2751270A4 (en) OLIGOMER CONJUGATE COMPLEXES AND ITS USE
IL233051B (en) Anti-phf-tau antibodies and uses thereof
IL229844B (en) Anti-psgl-1 antibodies and their use
ZA201404485B (en) Peer-to-peer payment registration and activation
EP2687555A4 (en) POLYAMIDE AND POLYAMIDE COMPOSITION
EP2716359A4 (en) COMPLEX AND USES THEREOF
GB201111775D0 (en) Compounds and uses thereof
EP2815141A4 (en) BEARING COMPONENT
EP2733361A4 (en) TURBO
PL2667710T3 (pl) Kompozycja owadobójcza i związane z nią sposoby
EP2693879A4 (en) MIGRASTATINES AND THEIR USES
EP2728198A4 (en) TURBO
GB201104522D0 (en) Complexes
EP2733360A4 (en) TURBO COMPRESSOR
GB201100924D0 (en) Surfaces
GB201211820D0 (en) Blisk manufacturing
GB201121726D0 (en) Compounds and uses thereof
GB201121551D0 (en) Compounds and uses thereof
GB201116360D0 (en) Glycobiological surfaces
LT3689878T (lt) 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk inhibitoriai
AU340099S (en) Trousers